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Abstract Substance use has been identified as a risk
factor for elevated levels of obsessive–compulsive disorder
(OCD). This study examined methamphetamine use and
sexual risk behaviors as correlates of OCD in a sample of
245 HIV-positive men having sex with men (MSM) in
San Diego, CA. In a logistic regression analysis, OCD was
associated with greater frequency of methamphetamine
use, more depressive symptoms, seeking out risky venues
and risky sexual partners when ‘‘high’’ on methamphet-
amine, and reporting fewer sex acts in the past 2 months.
These data suggest the need for increased awareness and
understanding of the role that OCD may play in the drug
use behaviors and risky sexual practices of methamphet-
amine users.
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Introduction
Previous research has shown that substance use disorders
(SUDs) are linked to a variety of co-morbid conditions,
including obsessive–compulsive disorder (OCD) [1, 2].
The prevalence of OCD among methamphetamine users
and the link between patterns of methamphetamine use and
OCD have not been studied. Moreover, there is little
information on the relationship between OCD and high-risk
sexual behaviors, which are common among metham-
phetamine users [3, 4]. We propose that successful treat-
ment of individuals with OCD and methamphetamine use
disorder may require addressing both conditions. To this
end, it is important to identify behaviors and conditions
that are associated with methamphetamine use and OCD
comorbidity. The present study examines substance use
patterns and sexual risk behaviors as correlates of OCD in a
high-risk and high-need population of HIV-positive meth-
amphetamine-using men who have sex with men (MSM).
Examining patterns of methamphetamine use, above and
beyond SUD diagnosis, may improve our understanding of
the links between OCD and SUDs. Although we were
unable to find studies that link frequency of drug use or
binge drug use to OCD, several studies have documented a
positive relationship between binge eating and OCD [5, 6].
Given that binge eating can have similar patterns to drug
use by those with SUD [7], a similar relationship may be
present between OCD and SUD.
There is a lack of studies that report on the sexual risk
behaviors of SUD patients with OCD comorbidity. How-
ever, in one study of non-substance users, the severity of
OCD symptoms was negatively correlated with relation-
ship intimacy, relationship satisfaction, and self-disclosure
of the disorder. Severity of OCD symptoms was also
positively associated with fears regarding contamination
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from sexual activity [8]. In another study, 24.9% of OCD
patients meeting DSM-IV criteria reported a history of
sexual obsessions [9], suggesting that this is a fairly com-
mon clinical feature of OCD.
In the general population, depressive disorders are
common among OCD patients [10]. McElroy et al. [11]
have suggested that OCD spectrum disorders belong to the
broader family of affective orders. In a study of axis I
comorbidity in OCD, major depression (MDD) was iden-
tified as the most common comorbidity, with 39.5% of
OCD patients presenting with MDD [12]. In another study
that examined the co-occurrence of depressive disorders in
OCD, one-third of the sample was diagnosed with
comorbid depression [13]. Moreover, studies that com-
pared OCD patients who have major depression with those
who do not have found significant differences in the pre-
sentation and clinical severity of symptoms [10, 14, 15],
suggesting the need to include a measure of depression in
studies of obsessive–compulsive disorders.
Studies that have examined risk factors and correlates of
obsessive–compulsive disorder have found few associa-
tions with demographic characteristics [16, 17]. OCD
symptoms typically begin before the age of 30, but cases
with later onset have been documented [18]. The onset of
symptoms tends to be gradual, and their development is
continuous regardless of age of onset [19]. In an epide-
miological study, OCD was found to affect mostly female
adults and male children and adolescents. Individuals who
were unmarried and abused drugs were also more likely to
have OCD symptoms [17].
The purpose of the current study is twofold: first, to
examine the prevalence of OCD in a sample of HIV-
positive, methamphetamine-using MSM, and second, to
identify behavioral correlates of OCD in this target popu-
lation. We hypothesized that methamphetamine use and
risky sexual behaviors would be associated with clinical
levels of OCD symptoms as measured by the Obsessive
Compulsive Inventory, Revised (OCI-R) [20].
Methods
Sample Selection
These analyses used baseline data from a sample of 245
men who were enrolled in a long-term efficacy study of
a sexual risk reduction intervention for HIV-positive,
methamphetamine-using MSM. The protocol entailed five
individual counseling sessions and eight group-based
maintenance sessions that used motivational interviewing
[21], social cognitive strategies [22], and cognitive
behavioral therapy [23] to reduce high-risk sexual practices
and maintain treatment effects. Eligible participants were
at least 18 years of age, self-identified as MSM, and
reported having had unprotected anal sex with at least one
same-sex partner during the previous 2 months. To avoid
the enrollment of one-time users of this drug, it was also
required that participants have used methamphetamine at
least twice during the past 2 months, and at least once
during the past 30 days. Recruitment sources included
community-based service providers, poster and media
campaigns, street outreach, and referrals from enrolled
participants. Interviews were conducted using audio-CASI
technology [24].
Measures
Obsessive–Compulsive Symptoms
To assess severity of OCD symptoms, we used the
Obsessive Compulsive Inventory Revised (OCI-R), which
consists of 18 items with six subscales. The subscales
include: washing, checking, ordering, obsessing, hoarding,
and neutralizing. Participants are asked to rate each item in
terms of how much they were bothered or distressed by a
specific experience. Sample items include: During the past
month, the following experience has bothered or distressed
me: (a) I have saved up so many things that they get in
the way (hoarding); (b) I check things more often than
necessary (checking); and (c) I am compelled to count
while doing things (neutralizing). Items are rated on a
4-point scale ranging from 0 (not at all) to 4 (extremely).
The OCI-R has good psychometric properties: internal
consistency for the full scale ranges from 0.81 to 0.93,
while test–retest reliability over a 2-week period was
reported as 0.71 to 0.91 for OCD patients. The OCI-R has
also been shown to have good discriminant validity and
good to excellent convergent validity [20]. As recom-
mended by Foa et al. [20], we used a cutpoint of 18 for
total OCI-R scores to identify participants with a clinical
level of OCD symptoms.
Methamphetamine Use Variables
The frequency of methamphetamine use was measured as
the number of days the participant used methamphetamine
in the past 30 days (‘‘During the past 30 days, on how
many days did you do meth?’’). A dichotomized variable
was created using a median split, where scores greater than
or equal to 11 (high frequency) were coded ‘‘1’’ and scores
less than 11 (low frequency) were coded ‘‘0’’. Binge use of
methamphetamine was assessed with a single question:
‘‘Are you a binge user? By binge user, we mean that you
keep using large quantities of methamphetamine for a
period of time, until you run out or just physically can’t do
it anymore.’’ Responses were coded 1 = yes, 0 = no.
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Sexual Risk Behaviors
Sexual risk behavior was defined as unprotected sex with
an opposite- or same-sex partner. For each sex partner,
participants were asked how many times during the past
2 months they had engaged in anal, oral, and vaginal sex.
A follow-up question was used to determine the number of
times a condom or dental dam was used. A dichotomous
variable was created to represent total number of sex acts
during the previous 2 months. The distribution, which was
positively skewed, was split at the second tertile so that a
high score on number of sex acts was defined as C45 sex
acts and a low score was\45. In addition, two scales, each
with three statements, were used to assess sexual risk
behaviors associated with methamphetamine use. Response
categories for all six statements ranged from 1 (Strongly
Disagree) to 4 (Strongly Agree). The first three-item scale
described vigorous sexual practices associated with meth-
amphetamine use. The statements were: ‘‘When I’m high
on meth: (a) I have sex until my genitals are raw, sore, or
bleeding; (b) sex is so vigorous that condoms sometimes
break or come off; and (c) oral sex is so intense that my
partner sometimes gets cuts and tears in his/her mouth or
penis.’’ The alpha for this scale in the present sample was
0.72. The second set of three items described the pursuit of
risky partners and risky sexual venues when high on
methamphetamine: ‘‘When I’m high on meth: (a) I seek out
risky sexual partners (e.g., anonymous partners, sex
workers); (b) I go to places where I know I can get sex; and
(c) I go cruising for sex partners at bookstores, parks or
bars.’’ Cronbach’s alpha for this scale in the present sample
was 0.79. Dichotomized variables were created for each
measure using a median split. For the vigorous sexual
practices scale, scores greater than or equal to 2 (high risk
behavior) were coded ‘‘1’’ and score less than 2 (low risk
behavior) were coded ‘‘0’’. For the risky partners and
risky venues scale, scores greater than or equal to 3 (high
risk behavior) were coded ‘‘1’’ and scores less than 3
(low risk behavior) were coded ‘‘0’’.
Depressive Symptoms
Depressive symptoms were assessed using the Beck
Depression Inventory (BDI-II) [25]. The BDI-II comprises
21 items, each having four graded statements that are
ordered (0–3) to show increasing depressive symptoms.
Because somatic symptoms of depression can be con-
founded with physical symptoms and patients with HIV
may be at higher risk for physical symptoms, we excluded
the somatic items on the BDI-II and used only the 13-item
cognitive-affective subscale in our analyses [26]. The
sensitivity of this subscale to detect clinical depression has
been demonstrated in previous studies [27]. Cronbach’s
alpha for the cognitive-affective subscale of the BDI-II in
this sample was 0.92, and scores ranged from 0 to 39. For
analytic purposes, a dichotomized variable was created
using a median split where scores greater than or equal to
10 (higher depressive symptoms) were coded ‘‘1’’ and
scores lower than 10 (lower depressive symptoms) were
coded ‘‘0’’.
Statistical Analysis
Since the total number of sex acts in the past 2 months yielded
a positively skewed distribution, we corrected for skewness
using a log 10 ? 1 transformation. A Kolmogorov–Smirnov
test of normality [28] indicated that the transformed number-
of-sex-acts variable approached a normal distribution
(p = 0.971). A logistic regression analysis was used to
identify correlates of clinical levels of OCD symptoms.
Participants who scored 18 or more on the OCI-R were
coded 1 (i.e., clinical level of OCD symptoms), and those
who scored less than 18 were coded 0 (non-clinical level of
OCD symptoms). Age was entered into the regression model
as a control variable. Variables of interest were subsequently
entered into the model simultaneously (i.e., number of days
methamphetamine used in the past month, binge use of
methamphetamine, cognitive-affective depressive symp-
toms, seek out risky venues and partners when ‘‘high’’ on
methamphetamine, engage in vigorous sex when ‘‘high’’ on
methamphetamine, and total number of sex acts in the past
2 months).
Results
Sample Description
By design, all participants were male. Participants were
predominantly Caucasian (56.3%), never married (84.1%),
living with another adult in a non-sexual relationship or
living alone (55.5%), unemployed (82.4%), with a 2-year
degree or some college (44.9%), and having an income of
less than $10,000 per year (47.8%). The average age
was 39.7 years (SD = 7.7, median = 40.0, range 18–61).
Mean number of days that participants used methamphet-
amine in the past 30 days was 12.0 (SD = 9.0, med-
ian = 10.0, range 1–30). Forty-three percent of the sample
self-identified as binge users of methamphetamine. Mean
number of grams of methamphetamine used in the
past 30 days was 9.5 (SD = 16.9, median = 3.5, range
0.05–135). The mean number of sex acts in the past
2 months was 46.1 (SD = 51.7, median = 29.0, range
2–300). The mean score on the cognitive-affective subscale
of the BDI-II was 10.6 (SD = 8.3, median = 10.0, range
0–37). Sample characteristics are presented in Table 1.
AIDS Behav (2011) 15:1153–1160 1155
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Table 1 Sample characteristics
of HIV-positive
methamphetamine-using MSM
(N = 245)
a OCI-R score C 18
b OCI-R score \ 18
Variable Clinical level
of OCD
symptomsa
(N = 64)
Non-clinical
level of OCD
symptomsb
(N = 181)
Test
statistic
p
value
Background characteristics
Sexual orientation v2 = 5.01 0.171
Gay or homosexual 76.6% 82.3%
Bisexual 23.4 16.0
Not sure 0.0 1.7
Ethnicity v2 = 1.09 0.780
Caucasian 56.3% 56.4%
African American 20.3 24.2
Latino 14.0 13.3
Other 9.4 6.1
Education v2 = 5.83 0.213
Less than high school 20.3% 9.4%
High school or equivalent 25.0 24.8
2-Year degree or some college 40.6 46.4
4-Year college degree 7.8 12.2
Graduate or advanced degree 6.3 7.2
Marital status v2 = 4.80 0.187
Never married 79.7% 85.6%
Married 0.0 1.1
Separated 3.1 5.0
Divorced 17.2 8.3
Living arrangement v2 = 34.36 0.000
With same sex spouse or steady 11.0% 13.2%
With opposite sex spouse or steady 3.2 0.0
With other adults who are not sexual partners 12.5 33.7
Alone 20.3 29.9
Homeless 29.6 7.7
Other 23.4 15.5
Income v2 = 3.52 0.620
Less than $10,000 51.6% 46.4%
$10,000–$19,999 35.8 38.7
$20,000–$29,999 1.6 6.6
$30,000–$39,999 4.7 2.8
$40,000–$49,999 1.6 2.2
$50,000 or more 4.7 3.3
Employed 14.1% 18.8% v2 = 0.73 0.258
Age (mean, SD) 38.4 (7.5) 40.1 (7.8) t = 1.52 0.130
Depression score (mean, SD) 16.7 (8.9) 8.4 (6.8) t = 7.7 0.000
Sexual and drug use behaviors
Binge use in past 2 months 48.4% 41.4% v2 = 0.94 0.204
Number of grams of methamphetamine used
(mean, SD)
8.8 (12.3) 9.2 (18.0) t = 0.162 0.871
Number of days methamphetamine used in past
30 days (mean, SD)
13.3 (10.6) 9.8 (8.7) t = 2.4 0.019
Number of sex acts in past 2 months (mean, SD) 42.4 (47.6) 47.4 (53.1) t = 0.46 0.643
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OCD Prevalence
The mean score on the 18-item OCI-R was 12.5
(SD = 11.1, median = 9.0, range 0–51). Using the OCI-R
cutpoint of 18 [20], 26.1% of our sample met clinical cri-
teria for OCD. We also examined participants’ scores on
subscales of the OCI-R (Table 2). The maximum score on
each subscale is 12. Washing, hoarding, and neutralizing
were significantly correlated with greater frequency of
methamphetamine use (r = 0.16, 0.12, 0.14, respectively,
p \ 0.05). The obsessing, ordering, and checking subscales
were not associated with methamphetamine use.
Factors Independently Associated with OCD
A single logistic regression analysis was performed to
identify factors associated with clinical levels of OCD
symptoms. Zero-order correlations among independent
variables ranged from -0.28 to 0.21. A test of the full model
with seven predictors against a constant-only model was
statistically significant (v2 = 50.2, p \ 0.001, -2 log like-
lihood = 230). In our age-adjusted model, MSM with high
depressive symptoms had more than five times the odds of
having a clinical level of OCD symptoms compared with
those who had low depressive symptoms. In addition,
MSM who scored high on ‘‘seeking risky partners and
venues when high on methamphetamine’’ had more than
double the odds of a clinical level of OCD symptoms
compared to those who scored low on this measure of
sexual risk behavior. Interestingly, men who reported a
high number of sexual acts in the past 2 months had a
lower odds of a clinical level of OCD symptoms compared
to those who reported a low number of sex acts during this
time frame. Frequency of methamphetamine use, measured
by number of days used in the past month, was also
associated with OCD. Participants who scored high on
frequency of methamphetamine use had a greater odds of
having a clinical level of OCD symptoms compared to
those who had low frequency of methamphetamine use
(see Table 3).
We conducted post hoc analyses to examine further the
association between OCD symptoms and total number of
sex acts, taking into account partner type and serostatus.
T test analyses yielded no differences in total number of sex
acts by OCD group when examined separately by partner
type (i.e., steady, casual, anonymous) or partner serostatus
(i.e., HIV-negative, unknown serostatus, HIV-positive).
Discussion
In our sample of HIV-positive, methamphetamine-using
MSM, clinical levels of OCD were associated with more
frequent use of methamphetamine, more depressive symp-
toms, and more risky sexual behaviors when ‘‘high’’ on
methamphetamine, but fewer sexual acts in a 2-month per-
iod. This profile suggests that efforts to treat methamphet-
amine use and promote safer sex practices in this target
population may require efforts to mitigate and treat severe
OCD symptoms.
Our finding that frequency of methamphetamine use was
positively associated with OCD is consistent with the lit-
erature on OCD and substance use (e.g., [2, 29]). The
clinical significance of the relationship between metham-
phetamine use and OCD may be that OCD patients who
use stimulants have worse treatment outcomes. Brady et al.
[30] described an OCD-like, compulsive foraging syn-
drome in cocaine-dependent individuals who in laboratory
tests were obsessed with finding misplaced cocaine. Since
this behavior has not been observed in persons with other
drug addictions [31], it could be hypothesized that people
who use stimulants and have severe OCD symptoms may
not respond as well to conventional drug treatment pro-
grams. More research is needed to clarify the impact of the
relationship between methamphetamine use and OCD on
drug treatment outcomes.
Participants who met the threshold for a clinical level of
OCD symptoms were also more likely to report seeking out
risky sexual venues and risky sexual partners when ‘‘high’’
on methamphetamine. The novelty-seeking and exciting
nature of risky sexual behaviors in the context of meth-
amphetamine use may be reinforcing, thus making these
behaviors more resistant to change. Accordingly, the
effectiveness of sexual risk reduction programs may be
enhanced by addressing OCD symptoms and teaching self-
regulation techniques (e.g., cognitive reframing, delaying)
that help individuals to manage their risky behaviors and
their obsessions and compulsions. In addition, future
studies should examine whether treatment for OCD is
associated with reductions in sexual risk behaviors.
Contrary to expectation, total number of sex acts in the
past 2 months was negatively associated with clinical
levels of OCD symptoms. Although we cannot completely
Table 2 Mean, standard deviation, median and range for OCI-R
subscales (N = 245)
OCI-R subscale Mean SD Median Range
Washing 1.37 1.87 1.00 0–11
Obsessing 2.38 2.75 1.00 0–12
Hoarding 2.69 2.42 2.00 0–11
Ordering 2.78 2.75 2.00 0–12
Checking 1.91 2.27 1.00 0–10
Neutralizing 1.39 2.04 1.00 0–12
AIDS Behav (2011) 15:1153–1160 1157
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rule out Type 1 error in these analyses, the bivariate
correlation indicates that the relationship is truly inverse.
A plausible explanation for our finding derives from the
literature regarding sexual dysfunction and OCD. In a
study that compared patients with OCD, major depressive
disorder (MDD), and generalized anxiety disorder (GAD),
Kendurkar and Kaur [32] reported that the rate of sexual
dysfunction was 50% for OCD patients. As did MDD and
GAD patients, OCD patients reported low sexual desire as
the most common source of sexual dysfunction. Thus, it is
not unreasonable to suggest that EDGE-II participants who
met clinical criteria for OCD experienced low levels of
sexual desire that was self-remedied by the use of meth-
amphetamine. This hypothesis warrants attention in future
studies.
Although this study focused on methamphetamine use
and sexual risk behaviors as correlates of OCD, it was
depressive symptoms, as measured by the cognitive-affec-
tive subscale of the BDI-II, that yielded the strongest rela-
tionship with OCD. This finding is consistent with previous
research, which has demonstrated the co-occurrence of
major depressive disorder and clinical levels of OCD [12,
13]. There is also evidence that depressed OCD patients have
more severe OCD symptoms compared to those without
comorbid depression [14, 15]. From a clinical perspective,
methamphetamine users who present with depressive
symptoms should also be screened for OCD symptoms.
Treatment programs that aim to reduce methamphetamine
use and depression might combine psycho-pharmacological
and psychotherapeutic treatments for OCD. A review of
pharmacological therapies [33] concluded that administra-
tion of fluvoxamine or sertraline (two commonly used
SSRIs) is the recommended treatment for OCD, with aug-
mentation for refractory patients using risperidone, olanza-
pine, or quetiapine. The recommended psychotherapeutic
treatment for OCD is cognitive behavioral therapy (CBT)
[34]. CBT has been shown clinically effective with OCD
patients using various methods of delivery, including indi-
vidual, group, and telephone [35, 36].
A primary limitation of this study stems from its use of a
convenience sample of HIV-positive, methamphetamine-
using MSM who were volunteers in a sexual risk reduction
intervention, since individuals who volunteer for research
projects may not be representative of the larger target
population. Another limitation stems from the self-report
nature of the measures for OCD symptoms, methamphet-
amine use, and sexual risk behaviors. Self-report is subject
to biases and inaccuracies in recall, particularly in relation
to sexual and drug-use behaviors. This study is also limited
by the use of a single question to measure binge use of
methamphetamine. As noted by Lange and Voas [37], the
concept of binging is inherently difficult to measure among
substance users, which may explain the absence of multi-
dimensional, standardized assessment tools. The single-
item measure used in this study appears to have face
validity; however, future studies should explore the validity
and reliability of this and other single-item measures.
Although the OCI-R has been shown to discriminate
between patients with OCD and anxious controls, sensi-
tivity and specificity of the cutpoints should be examined in
studies of patients with comorbid psychiatric disorders
(e.g., depressive disorders). The cross-sectional nature of
our data precludes us from making causal inferences
regarding the association between methamphetamine use
and OCD. Although some research has suggested that OCD
symptoms precede substance use [1], it is also possible that
methamphetamine use might induce OCD-like symptoms
that may or may not be reversible. Prospective research
designs are needed to address the issue of temporality to
inform inferences about causality. Lastly, it is also possible
that the relationship between methamphetamine use and
OCD is explained by a confounding variable (e.g., co-use of
other drugs, comorbid personality disorder) not considered
in this research.
Table 3 Factors independently associated with obsessive–compulsive disorder in a sample of HIV-positive methamphetamine-using MSM
(N = 243)
Variable Odds
ratio
95% confidence
interval
Age (per year increase) 0.96 0.92–1.01
Days per month of methamphetamine use (high frequency vs. low frequency) 1.04 1.01–1.08
Binge use of methamphetamine (vs. no binge use) 0.72 0.36–1.42
Cognitive-affective depressive symptoms (high distress vs. low distress) 5.56 2.68–11.52
Seek risky venues and partners when ‘‘high’’ on methamphetamine (high risk behavior vs. low risk behavior) 2.57 1.22–5.43
Engage in vigorous sex when ‘‘high’’ on methamphetamine (high risk behavior vs. low risk behavior) 1.34 0.65–2.73
Total number of sex acts in the past 2 months (high number of sex acts vs. low number of sex acts) 0.33 0.15–0.72
Two cases missing data
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Concluding Remarks
Overall, the present study suggests a need to increase
health care professionals’ awareness of OCD symptoms in
methamphetamine users. Our findings also suggest that the
combination of drug dependence, depressive symptoms,
and OCD may be common in methamphetamine users.
Future studies should seek to identify social, psychological,
and behavioral factors as well as clinical consequences
associated with this combination of morbidities.
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